AU2022287033B2 - Pyridopyrimidine derivatives useful as wee1 kinase inhibitors - Google Patents

Pyridopyrimidine derivatives useful as wee1 kinase inhibitors Download PDF

Info

Publication number
AU2022287033B2
AU2022287033B2 AU2022287033A AU2022287033A AU2022287033B2 AU 2022287033 B2 AU2022287033 B2 AU 2022287033B2 AU 2022287033 A AU2022287033 A AU 2022287033A AU 2022287033 A AU2022287033 A AU 2022287033A AU 2022287033 B2 AU2022287033 B2 AU 2022287033B2
Authority
AU
Australia
Prior art keywords
cancer
compound
tumor
cell
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022287033A
Other languages
English (en)
Other versions
AU2022287033A1 (en
Inventor
Oren GILAD
Joseph Vacca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aprea Therapeutics Inc
Original Assignee
Aprea Therapeutics Inc
Aprea Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprea Therapeutics Inc, Aprea Therapeutics Inc filed Critical Aprea Therapeutics Inc
Publication of AU2022287033A1 publication Critical patent/AU2022287033A1/en
Application granted granted Critical
Publication of AU2022287033B2 publication Critical patent/AU2022287033B2/en
Priority to AU2025204724A priority Critical patent/AU2025204724A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022287033A 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors Active AU2022287033B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204724A AU2025204724A1 (en) 2021-06-04 2025-06-23 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196744P 2021-06-04 2021-06-04
US63/196,744 2021-06-04
PCT/US2022/032203 WO2022256680A1 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204724A Division AU2025204724A1 (en) 2021-06-04 2025-06-23 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Publications (2)

Publication Number Publication Date
AU2022287033A1 AU2022287033A1 (en) 2024-01-18
AU2022287033B2 true AU2022287033B2 (en) 2025-04-17

Family

ID=82321319

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2022287033A Active AU2022287033B2 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
AU2025204724A Pending AU2025204724A1 (en) 2021-06-04 2025-06-23 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204724A Pending AU2025204724A1 (en) 2021-06-04 2025-06-23 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Country Status (10)

Country Link
US (1) US20240254123A1 (https=)
EP (1) EP4347592A1 (https=)
JP (1) JP2024522304A (https=)
KR (1) KR20240044409A (https=)
CN (1) CN117794932A (https=)
AU (2) AU2022287033B2 (https=)
CA (1) CA3225152A1 (https=)
IL (1) IL309037A (https=)
MX (1) MX2023014466A (https=)
WO (1) WO2022256680A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315441A (en) 2022-03-07 2024-11-01 Debiopharm Int Sa Treatment methods for small cell lung cancer
IL326854A (en) 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
CN120189510A (zh) * 2023-12-21 2025-06-24 北京哲源科技有限责任公司 一种并环化合物的应用
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014167347A1 (en) * 2013-04-11 2014-10-16 Almac Discovery Limited 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
WO2018011570A1 (en) * 2016-07-12 2018-01-18 Almac Discovery Limited Wee-1 inhibiting pyridopyrimidinone compounds
WO2019138227A1 (en) * 2018-01-10 2019-07-18 Almac Discovery Limited Pharmaceutical compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CA3071405A1 (en) * 2017-08-01 2019-02-07 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2014167347A1 (en) * 2013-04-11 2014-10-16 Almac Discovery Limited 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors
WO2018011570A1 (en) * 2016-07-12 2018-01-18 Almac Discovery Limited Wee-1 inhibiting pyridopyrimidinone compounds
WO2019138227A1 (en) * 2018-01-10 2019-07-18 Almac Discovery Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2025204724A1 (en) 2025-07-10
CA3225152A1 (en) 2022-12-08
KR20240044409A (ko) 2024-04-04
AU2022287033A1 (en) 2024-01-18
CN117794932A (zh) 2024-03-29
WO2022256680A1 (en) 2022-12-08
US20240254123A1 (en) 2024-08-01
IL309037A (en) 2024-02-01
MX2023014466A (es) 2024-05-02
EP4347592A1 (en) 2024-04-10
JP2024522304A (ja) 2024-06-13

Similar Documents

Publication Publication Date Title
AU2022287033B2 (en) Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
AU2017241837B2 (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
JP6633744B2 (ja) 医薬組成物及びその応用
US20240316004A1 (en) Methods of treating mutant lymphomas
CN104042618B (zh) 恶性血液病的治疗
CA3066939A1 (en) Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
CA3080971A1 (en) Modulators of the integrated stress pathway
US20250108052A1 (en) Immunophilin binding agents and uses thereof
ES2895419T3 (es) Formas sólidas de (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-piran-4-il)amino)-8-((2,4,6-triclorofenil)amino)-9H-purin-9-il)-1-metilciclohexan-1-carboxamida y métodos para su uso
AU2011261185A1 (en) The use of inhibitors of Bruton's tyrosine kinase (Btk)
US20200095260A1 (en) Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
US20190142834A1 (en) Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
KR20250067120A (ko) 의학적 치료를 위한 시클린-의존성 키나제 2 억제제
TW201609106A (zh) 用於治療ｃｎｓ惡性病之ｂｔｋ抑制劑
US11780815B2 (en) DNA2 inhibitors for cancer treatment
HK40107981A (zh) 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物
CA2845095A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)